Mass Vaccination: When and Why

  • D. L. Heymann
  • R. B. Aylward
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 304)

Abstract

With increased demand for smallpox vaccination during the nineteenth century, vaccination days—early mass vaccination campaigns—were conducted over time-limited periods to rapidly and efficiently protect maximum numbers of susceptible persons. Two centuries later, the challenge to rapidly and efficiently protect populations by mass vaccintion continues, despite the strengthening of routine immunization services in many countries through the Expanded Programme on Immunization strategies and GAVI support. Perhaps the most widely accepted reason for mass vaccination is to rapidly increase population (herd) immunity in the setting of an existing or potential outbreak, thereby limiting the morbidity and mortality that might result, especially when there has been no routine vaccination, or because populations have been displaced and routine immunization services disrupted. A second important use of mass vaccination is to accelerate disease control to rapidly increase coverage with a new vaccine at the time of its introduction into routine immunization programmes, and to attain the herd immunity levels required to meet international targets for eradication and mortality reduction. In the twenty-first century, mass vaccination and routine immunization remain a necessary alliance for attaining both national and international goals in the control of vaccine preventable disease.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hopkins DR (1983) Princes and peasants: Smallpox in history. University of Chicago Press, ChicagoGoogle Scholar
  2. 2.
    Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Smallpox and its eradication. World Health Organization, Geneva p 263Google Scholar
  3. 3.
    McLeod RM (1967) Law, Medicine and public opinion: the resistance to compulsory health legislation 1870–1907. Public Law 1967:6: 107–128, 189–211Google Scholar
  4. 4.
    Edwards EJ (1902) A concise history of small-pox and vaccination in Europe. London, LewisGoogle Scholar
  5. 5.
    World Health Organization, 1966. World Health Assembly 19.16Google Scholar
  6. 6.
    Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Smallpox and its eradication. World Health Organization, Geneva, pp 296–309Google Scholar
  7. 7.
    Fenner F, Henderson DA, Arita I, Jezêk X, Ladnyi ID (1988) Developments in Vaccination and Control: Smallpox and its Eradication. World Health Organization, Geneva, p 175Google Scholar
  8. 8.
    Fenner F, Henderson DA, Arita I, Jezêk X, LadnyiI D (1988) Developments in Vaccination and Control: Smallpox and its Eradication. World Health Organization, Geneva, p 1363–1365Google Scholar
  9. 9.
    Barrett S, Hoel M (2003) Optimal disease eradication. Frisch Centre, University of Oslo 203 (HERO working paper 23/2003)Google Scholar
  10. 10.
    Sencer JD, Axnick NW (1973) Cost benefit analysis. Immunological Standardization 22:37–46Google Scholar
  11. 11.
    Gonzalez CL (1965) Mass campaigns and general health services. World Health Organization, Geneva. Public Health Papers, no. 29Google Scholar
  12. 12.
    Mills A (2005) Mass campaigns versus general health services: what we have learnt in 40 years about vertical versus horizontal approaches. Bull World Health Org 83(4): 315–316PubMedGoogle Scholar
  13. 13.
    Henderson RH, Keja K, Galazka AM, Chan CA (1990) Reaping the benefits: getting vaccines to those who need them. In: Woodrow GC, Levine MM (eds). New Generation vaccines. Marcel Dekker, New York, pp 69–82Google Scholar
  14. 14.
    Henderson RH, Keja J, Hayden G, et al. (1988) Immunizing children of the world: progress and prospects. Bull World Health Org 66:535–543PubMedGoogle Scholar
  15. 15.
    Keegan R, Bilous J (2004) Current issues in global immunizations. Seminars in Pediatric Infectious Diseases. Elsevier, AmsterdamGoogle Scholar
  16. 16.
    Muraskin W (2004) The global alliance for vaccines and immunization: is it a new model for effective public-private cooperation in international public health? Am J Public Health 94:11:1922–1925PubMedCrossRefGoogle Scholar
  17. 17.
    World Health Organization. “First, do no harm”. Introducing auto-disable syringes and ensuring injection safety in immunization systems of developing countries. WHO/V&B/02.26Google Scholar
  18. 18.
    Greenwood BM (1987) The epidemiology of acute bacterial meningitis in tropical Africa. In: Williams JD, Brunie J (eds). Bacterial meningitis. Academic Press, London, pp 61–91Google Scholar
  19. 19.
    Reingold AL, Broome CV, Hightower A, et al. (1985) Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 2:112–118Google Scholar
  20. 20.
    Schwartz B, Moore PS, Broome CV (1989) Global epidemiology of meningococcal disease. Clin Microbiol Rev 2:S118–S124PubMedGoogle Scholar
  21. 21.
    World Health Organization. Control of Epidemic meningococcal disease. WHO practical guidelines: second edition:WHO/EMC/BAC/98.3Google Scholar
  22. 22.
    Stohr K (2004) Influenza. In: Heymann DL (ed). Control of communicable diseases manual 18th edition, an official report of the American Public Health AssociationGoogle Scholar
  23. 23.
    Heymann DL (2005) Preparing for a New Global Threat—Part I. YaleGlobal, 26 January 2005. http://yaleglobal.yale.edu/display.article?id=5174Google Scholar
  24. 24.
    World Health Organization, 2000. Yellow Fever. WHO/EPI/GEN/98.11, WHO/CDS/EDC/2000.2Google Scholar
  25. 25.
    Connolly MA, Gayer M, Ryan MJ, Salama P, Spiegel P, Heymann DL (2004) Communicable Diseases in Complex Emergencies-impacts and challenges. Lancet 364:1974–83PubMedCrossRefGoogle Scholar
  26. 26.
    World Health Organization (2004) Public health response to biological and chemical weapons, second editionGoogle Scholar
  27. 27.
    Heymann DL (2004) Smallpox containment updated: considerations for the 21st century. Int J Infect Dis 8(S2):S15–S20 (ISSN 1201-9712)PubMedCrossRefGoogle Scholar
  28. 28.
    World Health Organization. Control of rubella and congenital rubella syndrome in developing countries. WHO/V&B/00.03Google Scholar
  29. 29.
    World Health Organization. Yellow Fever. WHO/EPI/GEN/98.11, WHO/CDS/EDC/2000.2Google Scholar
  30. 30.
    Heymann DL, Aylward RB (2004) Perspective article. Global Health: Eradicating Polio. New Engl J Med 351(13):1275–1277PubMedCrossRefGoogle Scholar
  31. 31.
    Melgaard B, Creese A, Aylward B, Olivé J-M, Maher C, Okwo-Bele J-M, Lee JW (1998) Disease eradication and health systems development. Bull World Health Org (Suppl 2): 28–31Google Scholar
  32. 32.
    Dowdle WR (1998) The principles of disease elimination and eradication. Bull World Health Org (Suppl 2): 22–25Google Scholar
  33. 33.
    Bielik R, Madema S, Taole A, Kutsulukuta A, Allies E, Eggers RN, Ngcobo N, Nxumalo M, Shearley A, Mabuzane E, Kufa E, Okwo-Bele J-M (2002). First 5 years of measles elimination in southern Africa: 1996–2000. Lancet 359(9137):1564–1568CrossRefGoogle Scholar
  34. 34.
    World Health Organization. Field manual for neonatal tetanus elimination. WHO/V&B/99.14Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • D. L. Heymann
    • 1
  • R. B. Aylward
    • 1
  1. 1.World Health OrganizationSwitzerland

Personalised recommendations